Literature DB >> 16818927

Narrative review: Assessment of C-reactive protein in risk prediction for cardiovascular disease.

Donald M Lloyd-Jones1, Kiang Liu, Lu Tian, Philip Greenland.   

Abstract

Some experts propose C-reactive protein (CRP) as a screening tool for prediction of cardiovascular disease (CVD). Many epidemiologic studies show positive associations between elevated CRP levels and incident CVD. Assessment of the value of new prognostic tests, however, must rely on understanding of test characteristics rather than on associations measured by relative risks. In the case of CRP, test characteristics must be judged in the context of currently available CVD risk prediction algorithms. In this review of literature published before January 2006, the authors describe what is known about the additional utility of CRP in risk prediction. They find no definitive evidence that, for most individuals, CRP adds substantial predictive value above that provided by risk estimation using traditional risk factors for CVD. Use of CRP may add to risk estimation in a limited subset of individuals who are at intermediate predicted risk according to the Framingham risk score. The authors propose that many questions still must be addressed before CRP is incorporated into risk prediction algorithms and before universal screening with CRP can be recommended.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16818927     DOI: 10.7326/0003-4819-145-1-200607040-00129

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  68 in total

1.  Interleukin-6, interleukin-6 receptor gene variant, small-vessel disease and incident dementia.

Authors:  K Miwa; S Okazaki; M Sakaguchi; H Mochizuki; K Kitagawa
Journal:  Eur J Neurol       Date:  2016-01-03       Impact factor: 6.089

Review 2.  Analysis of biomarker data: logs, odds ratios, and receiver operating characteristic curves.

Authors:  Birgit Grund; Caroline Sabin
Journal:  Curr Opin HIV AIDS       Date:  2010-11       Impact factor: 4.283

3.  New Zealand cardiovascular guidelines: best practice evidence-based guideline: the assessment and management of cardiovascular risk December 2003.

Authors:  Michael Crooke
Journal:  Clin Biochem Rev       Date:  2007-02

Review 4.  Novel biochemical risk factors for type 2 diabetes: pathogenic insights or prediction possibilities?

Authors:  N Sattar; S G Wannamethee; N G Forouhi
Journal:  Diabetologia       Date:  2008-04-08       Impact factor: 10.122

5.  Attenuated NOx responses and myocardial ischemia, a possible risk for structural vascular disease in African men: the SABPA study.

Authors:  A S Uys; L Malan; J M van Rooyen; H S Steyn; M Reimann; T Ziemssen
Journal:  J Hum Hypertens       Date:  2014-01-09       Impact factor: 3.012

6.  Understanding the connection between spiritual well-being and physical health: an examination of ambulatory blood pressure, inflammation, blood lipids and fasting glucose.

Authors:  Julianne Holt-Lunstad; Patrick R Steffen; Jonathan Sandberg; Bryan Jensen
Journal:  J Behav Med       Date:  2011-04-13

Review 7.  Considering the inclusion of metabolic and cardiovascular markers in the Panel Study of Income Dynamics.

Authors:  Noreen Goldman; Jennifer B Dowd
Journal:  Biodemography Soc Biol       Date:  2009

8.  Circulating Vascular Growth Factors and Magnetic Resonance Imaging Markers of Small Vessel Disease and Atrophy in Middle-Aged Adults.

Authors:  Mekala R Raman; Jayandra J Himali; Sarah C Conner; Charles DeCarli; Ramachandran S Vasan; Alexa S Beiser; Sudha Seshadri; Pauline Maillard; Claudia L Satizabal
Journal:  Stroke       Date:  2018-09       Impact factor: 7.914

9.  Discordances among different tools used to estimate cardiovascular risk in postmenopausal women.

Authors:  Pascal Pelletier; Annie Lapointe; Nathalie Laflamme; Marie-Eve Piché; Stanley John Weisnagel; André Nadeau; Simone Lemieux; Jean Bergeron
Journal:  Can J Cardiol       Date:  2009-12       Impact factor: 5.223

10.  Effect of renin angiotensin system blockade on pentraxin 3 levels in type-2 diabetic patients with proteinuria.

Authors:  Mahmut Ilker Yilmaz; Jonas Axelsson; Alper Sonmez; Juan Jesus Carrero; Mutlu Saglam; Tayfun Eyileten; Kayser Caglar; Alper Kirkpantur; Turgay Celik; Yusuf Oguz; Abdulgaffar Vural; Mujdat Yenicesu; Bengt Lindholm; Peter Stenvinkel
Journal:  Clin J Am Soc Nephrol       Date:  2009-02-11       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.